Cns Pharmaceuticals Inc (CNSP)

Currency in USD
5.940
+0.210(+3.66%)
Closed·
5.9400.000(0.00%)
·
CNSP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.6405.990
52 wk Range
1.90010.588
Key Statistics
Prev. Close
5.73
Open
5.64
Day's Range
5.64-5.99
52 wk Range
1.9-10.588
Volume
10.56K
Average Volume (3m)
10.59K
1-Year Change
-10%
Book Value / Share
12.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CNSP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.000
Upside
+68.35%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Cns Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.000
(+68.35% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy20.00+236.70%-UpgradeSep 12, 2025

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.38 / -0.69
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CNSP Income Statement

Compare CNSP to Peers and Sector

Metrics to compare
CNSP
Peers
Sector
Relationship
P/E Ratio
−0.5x−1.3x−0.4x
PEG Ratio
−0.010.000.00
Price/Book
0.5x3.1x2.6x
Price / LTM Sales
-13.7x3.0x
Upside (Analyst Target)
70.8%516.9%49.7%
Fair Value Upside
Unlock0.0%6.8%Unlock

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
26.10K1.79%149.54K
Other Institutional Investors
337.88K23.12%1.94M
Public Companies & Retail Investors
1.10M75.09%6.29M
Total
1.46M100.00%8.37M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Ikarian Capital, LLC9.29%135,830778
ADAR1 Capital Management, LLC4.79%70,000401

People Also Watch

3.140
CXAI
-7.92%
0.2704
COSM
-1.02%
0.880
QTEX
+5.52%
0.9253
HYFM
-3.01%
5.9100
FCUV
-65.24%

FAQ

What Is the Cns Pharma (CNSP) Stock Price Today?

The Cns Pharma stock price today is 5.940 USD.

What Stock Exchange Does Cns Pharma Trade On?

Cns Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cns Pharma?

The stock symbol for Cns Pharma is "CNSP."

What Is the Cns Pharma Market Cap?

As of today, Cns Pharma market cap is 8.680M USD.

What Is Cns Pharma's Earnings Per Share (TTM)?

The Cns Pharma EPS (TTM) is -7.657.

When Is the Next Cns Pharma Earnings Date?

Cns Pharma will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is CNSP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cns Pharma Stock Split?

Cns Pharma has split 4 times.

How Many Employees Does Cns Pharma Have?

Cns Pharma has 8 employees.

What is the current trading status of Cns Pharma (CNSP)?

As of Sep 09, 2026, Cns Pharma (CNSP) is trading at a price of 5.940 USD, with a previous close of 5.730 USD. The stock has fluctuated within a day range of 5.640 USD to 5.990 USD, while its 52-week range spans from 1.900 USD to 10.588 USD.

What Is Cns Pharma (CNSP) Price Target According to Analysts?

The average 12-month price target for Cns Pharma is 10.000 USD, with a high estimate of 10 USD and a low estimate of 10 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +68.35% Upside potential.

What Is the CNSP Premarket Price?

CNSP's last pre-market stock price is 5.560 USD. The pre-market share volume is 710.000, and the stock has decreased by -0.170, or -2.970%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.